RLMD News and Press, Relmada Therapeutics Inc. From 04/28/20

NEW YORK , April 28, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointment of Brian A. Walter , Ph.D., as Vice President of Regul...

Allscripts Healthcare Solutions (NASDAQ: MDRX ) initiated with Outperform rating and $8 (21% upside) price target at RBC. More news on: Allscripts Healthcare Solutions, Inc., Aprea Therapeutics, Inc., Avita Medical Limited, Healthcare stocks news, Stocks on the move, , Read more ...

NEW YORK , March 31, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointment of Marc de Somer , MD, MBA, ScD, MPH, MSc, as  Se...

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 150 weeks of public selections as part of this ongoing live forward-testing. In...

NEW YORK , March 24, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointment of Judy Caron , Ph.D., as Vice President of Drug Developmen...

NEW YORK , March 9, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Thomas C. Wessel , M.D., Ph.D., has been appointed the Company's Execut...

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 147 weeks of public selections as part of this ongoing live forward-testing. In...

NEW YORK , Feb. 25, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Sergio Traversa , Chief Executive Officer of Relmada, will present a co...

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 145 weeks of public selections as part of this ongoing live forward-testing. In...

Today, we will study why Relmada Therapeutics (RLMD) is an attractive clinical-stage biopharmaceutical pick in 2020. Company overview Relmada Therapeutics is a clinical-stage biotechnology company focused on advancing REL-1017 (d-methadone or dextromethadone) as a rapid-acting oral treat...